Synopsis Bisphosphonates are known to prevent fracture in postmenopausal osteoporosis. However, their efficacy is uncertain in patients with osteopenia. This week’s “ MED FACT ” discusses a randomized, double-blind, placebo-controlled trial from The New England Journal of Medicine, “ Fracture Prevention with Zoledronate in Older Women with Osteopenia ”, 2018 Authors: I.R. Reid, A.M. Horne, B. Mihov, et.
al. Key Takeaways The risk of fragility fractures was significantly lower in postmenopausal women with osteopenia who received zoledronate than in women who received placebo. Objective: To determine the efficacy of zoledronate for fracture prevention in osteopenic postmenopausal women. Study Type: Randomized, double-blind, placebo-controlled trial Participants: 2000 What Was The Need Of This Study? Bisphosphonates prevent fractures in patients with osteoporosis; however, their efficacy…
